医学临床研究
  2025年4月4日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2023, Vol. 40 Issue (10): 1504-1507    DOI: 10.3969/j.issn.1671-7171.2023.10.018
  论著 本期目录 | 过刊浏览 | 高级检索 |
醋酸亮丙瑞林联合地屈孕酮治疗卵巢型子宫内膜异位症患者的疗效及对术后复发的影响
姜丽1, 樊亚婷2, 王莹2, 王新惠2*
1.宝鸡高新医院妇科,陕西 宝鸡 721300;
2.宝鸡市人民医院妇产科,陕西 宝鸡 721000
Effect of Leuprorelin Acetate Combined with Dydrogesterone on Ovarian Endometriosis Patients and its Influence on Postoperative Recurrence
JIANG Li, FAN Yating, WANG Ying, et al
Department of Gynecology, Baoji High-tech Zone Hospital, Baoji Shaanxi 721300
全文: PDF (1178 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨醋酸亮丙瑞林联合地屈孕酮治疗卵巢型子宫内膜异位症患者的疗效及对术后复发的影响。【方法】选择2019年8月至2021年6月宝鸡高新医院收治的110例卵巢型子宫内膜异位症患者,按照随机数字表法分为观察组和对照组,每组55例。两组均接受腹腔镜手术治疗,对照组术后接受醋酸亮丙瑞林治疗,观察组术后在对照组的基础上接受地屈孕酮治疗,两组均治疗3个月。比较两组临床疗效、不良反应、术后复发情况及治疗前后黄体生成素(LH)、促卵泡生成素(FSH)、雌二醇(E2)和盆腔痛、痛经、性交痛视觉模拟评分(VAS)。【结果】治疗后1年,观察组总有效率高于对照组(P<0.05);治疗后,两组血清FSH、LH、E2水平低于治疗前(P<0.05),且观察组血清FSH、LH、E2水平低于对照组(P<0.05);治疗后,两组盆腔痛、痛经、性交痛VAS均低于治疗前(P<0.05),且观察组盆腔痛、痛经、性交痛VAS低于对照组(P<0.05);两组总不良反应发生率比较,差异无统计学意义(P>0.05);随访1年,对照组失访1例,观察组失访2例,随访率为97.27%(107/110),观察组术后复发率(3.77%)低于对照组(16.67%)(P<0.05)。【结论】醋酸亮丙瑞林联合地屈孕酮治疗卵巢型子宫内膜异位症的疗效确切,可改善患者血清激素水平,减轻盆腔痛、痛经、性交痛,降低术后复发风险,且安全可靠。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
姜丽
樊亚婷
王莹
王新惠
关键词 子宫内膜异位症卵巢亮丙瑞林/药理学地屈孕酮/药理学    
Abstract:【Objective】To investigate the effect of Leuprorelin acetate combined with Dydrogesterone on ovarian endometriosis patients and its influence on postoperative recurrence. 【Methods】A total of 110 patients with ovarian endometriosis admitted to Baoji High-tech Zone Hospital from August 2019 to June 2021 were selected and divided into observation group and control group according to the random number table method, with 55 cases in each group. Both groups received laparoscopic surgery. The control group received leuprorelin acetate treatment after surgery, while the observation group received dydrogesterone treatment on the basis of the control group. Both groups were treated for 3 months. The clinical efficacy, adverse reactions, postoperative recurrence, serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), visual analogue scale (VAS) scores for pelvic pain, dysmenorrhea, and dyspareunia before and after treatment were compared between the two groups. 【Results】One year after treatment, the total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the serum FSH, LH, E2 levels of both groups were lower than those before treatment (P<0.05), and the serum FSH, LH, E2 levels of the observation group were lower than those of the control group (P<0.05). After treatment, the VAS scores for pelvic pain, dysmenorrhea, and dyspareunia in both groups were lower than those before treatment (P<0.05), and the VAS scores for pelvic pain, dysmenorrhea, and dyspareunia in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). During the follow-up period of one year, one patient in the control group and two patients in the observation group were lost to follow-up, resulting in a follow-up rate of 97.27%(107/110). The postoperative recurrence rate in the observation group (3.77%) was lower than that in the control group (16.67%) (P<0.05). 【Conclusion 】 Leuprorelin acetate combined with Dydrogesterone is effective in treating ovarian endometriosis. It can improve serum hormone levels, reduce pelvic pain, dysmenorrhea, dyspareunia, and postoperative recurrence risk with good safety and reliability.
Key wordsEndometriosis    Ovary    Leuprorelin/PD    Dydrogesterone/PD
收稿日期: 2023-08-01     
中图分类号:  R711.71  
通讯作者: *E-mail:Rmyyckwxh@163.com   
引用本文:   
姜丽, 樊亚婷, 王莹, 王新惠. 醋酸亮丙瑞林联合地屈孕酮治疗卵巢型子宫内膜异位症患者的疗效及对术后复发的影响[J]. 医学临床研究, 2023, 40(10): 1504-1507.
JIANG Li, FAN Yating, WANG Ying, et al. Effect of Leuprorelin Acetate Combined with Dydrogesterone on Ovarian Endometriosis Patients and its Influence on Postoperative Recurrence. JOURNAL OF CLINICAL RESEARCH, 2023, 40(10): 1504-1507.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.10.018     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I10/1504
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn